fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ICML 2017: How will Hodgkins lymphoma be managed in 2020?

Written by | 11 Jul 2017

By Maria Dalby (article) and Esther Drain (interviews) Not only is the treatment ‘landscape’ in Hodgkin lymphoma (HL) changing rapidly both in the first-line and relapsed/refractory setting, but… read more.

BSH 2017: Management of Asymptomatic Follicular Lymphoma

Written by | 24 Apr 2017

The old mantra is that advanced follicular lymphoma (FL) cannot be cured and treatment does not influence survival but this is no longer the case – follicular lymphoma… read more.

Liver tissue ‘reprogrammed’ to make pancreas cells

Written by | 19 Apr 2017

Scientists in Germany have successfully reprogrammed liver cells, turning them into pancreas progenitor cells by altering a single gene. The team behind the breakthrough, at the Max Delbrück… read more.

Liver tissue 'reprogrammed' to make pancreas cells

Written by | 19 Apr 2017

Scientists in Germany have successfully reprogrammed liver cells, turning them into pancreas progenitor cells by altering a single gene. The team behind the breakthrough, at the Max Delbrück… read more.

BSH 2017 Debate: Identification and novel management strategies are essential for double hit lymphoma

Written by | 14 Apr 2017

Double-hit lymphoma has a poor prognosis and the best option for patients could be positive identification and treatment with novel agents, but there are arguments for and against… read more.

BSH 2017: Cancer-related chronic fatique – internet and digital technology solutions

Written by | 14 Apr 2017

Chronic, cancer-related fatigue (CRF) is associated with a sudden- onset, profound lack of energy that is not relieved by rest. It is different from the fatigue experienced by… read more.

BSH 2017: Plenary debate: Allogeneic transplantation should be considered for selected young patients

Written by | 14 Apr 2017

Even in the era of novel therapies for newly-diagnosed and relapsed/refractory MM, there is a group of patients for whom the myeloma biology significantly shortens life expectancy. Allogeneic… read more.

BSH 2017: Myeloma XI

Written by | 14 Apr 2017

Maintenance therapy with lenalidomide can improve PFS in patients with newly-diagnosed MM by almost two years compared with observation alone, in patients of all ages and all risk… read more.

Get involved in ECCO

Written by | 11 Apr 2017

Commentary and insights from Dr Filip Baert, (Roeselare, Belgium) and Usha Chauhan (McMaster University, Canada)  

BSH 2017: How I treat molecular high-risk myeloma – what can we do, what should we do?

Written by | 6 Apr 2017

High-risk multiple myeloma (MM) continues to pose a challenge to haematologists both in terms of diagnostics and therapy. Opening the UK Myeloma Forum at the 2017 BSH annual… read more.

BSH 2017: Are we ready to use minimum residual disease to direct therapy?

Written by | 4 Apr 2017

Studies show that MM patients who achieve minimal residual disease on treatment have longer PFS and OS than those who do not…

ECCO 2017: Highlights

Written by | 4 Apr 2017

If you missed ECCO this year, or if you attended, but didn’t get to see everything you’d hoped to, listen to the key highlights from Professor Séverine Vermeire… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.